Please assess the completion status of the following clinical trial:

Trial Title: Anti-Androgen Treatment for COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male age ≥18 years old~2. Laboratory confirmed positive SARS-CoV-2 rtPCR test within 7 days prior to randomization~3. Clinical status on the COVID-19 8-point Ordinal Scale of 1 or 2~4. Coagulation: INR ≤ 1.5×ULN, and APTT ≤ 1.5×ULN~5. Subject (or legally authorized representative) gives written informed consent prior to any study screening procedures~6. Subject (or legally authorized representative) agree that subject will not participate in another COVID-19 trial while participating in this study~Exclusion Criteria:~1. Subject enrolled in a study to investigate a treatment for COVID-19~2. Subject taking an anti-androgen of any type including: androgen depravation therapy, 5-alpha reductase inhibitors, etc...~3. Patients who are allergic to the investigational product or similar drugs (or any excipients);~4. Subjects who have malignant tumors in the past 5 years, with the exception of completed resected basal cell and squamous cell skin cancer and completely resected carcinoma in situ of any type~5. Subjects with known serious cardiovascular diseases, congenital long QT syndrome, torsade de pointes, myocardial infarction in the past 6 months, or arterial thrombosis, or unstable angina pectoris, or congestive heart failure which is classified as New York Heart Association (NYHA) class 3 or higher, or left ventricular ejection fraction (LVEF) \< 50%, QTcF \> 450 ms~6. Subjects with uncontrolled medical conditions that could compromise participation in the study(e.g. uncontrolled hypertension, hypothyroidism, diabetes mellitus)~7. Known diagnosis of human immunodeficiency virus(HIV) , hepatitis C, active hepatitis B, treponema pallidum (testing is not mandatory）~8. Alanine Transaminase (ALT) or Aspartate Transaminase (AST) \> 5 times the upper limit of normal.~9. Estimated glomerular filtration rate (eGFR) \< 30 ml/min~10. Severe kidney disease requiring dialysis~11. Subject unlikely to return for day 15 site visit for reasons other then remission~12. Subject (or legally authorized representative) not willing or unable to provide informed consent

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Usual Care (Type: ACTIVE_COMPARATOR): Usual care as determined by the PI
- Proxalutamide + Usual Care (Type: EXPERIMENTAL): Proxalutamide + Usual care as determined by the PI

Based on this trial design, predict the completion outcome and termination type (if applicable).